PROCTER & GAMBLE HEALTH | AUROBINDO PHARMA | PROCTER & GAMBLE HEALTH/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.8 | 23.2 | 149.5% | View Chart |
P/BV | x | 10.6 | 2.4 | 440.6% | View Chart |
Dividend Yield | % | 2.0 | 0.3 | 735.5% |
PROCTER & GAMBLE HEALTH AUROBINDO PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
AUROBINDO PHARMA Mar-23 |
PROCTER & GAMBLE HEALTH/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 715 | 750.9% | |
Low | Rs | 3,883 | 397 | 977.3% | |
Sales per share (Unadj.) | Rs | 740.7 | 424.2 | 174.6% | |
Earnings per share (Unadj.) | Rs | 138.2 | 32.9 | 420.2% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 54.1 | 286.6% | |
Dividends per share (Unadj.) | Rs | 95.00 | 3.00 | 3,166.7% | |
Avg Dividend yield | % | 2.1 | 0.5 | 380.7% | |
Book value per share (Unadj.) | Rs | 447.6 | 458.1 | 97.7% | |
Shares outstanding (eoy) | m | 16.60 | 585.94 | 2.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 1.3 | 476.3% | |
Avg P/E ratio | x | 33.5 | 16.9 | 197.9% | |
P/CF ratio (eoy) | x | 29.8 | 10.3 | 290.2% | |
Price / Book Value ratio | x | 10.3 | 1.2 | 851.2% | |
Dividend payout | % | 68.7 | 9.1 | 753.6% | |
Avg Mkt Cap | Rs m | 76,761 | 325,753 | 23.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 35,223 | 5.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 248,554 | 4.9% | |
Other income | Rs m | 184 | 2,906 | 6.3% | |
Total revenues | Rs m | 12,480 | 251,460 | 5.0% | |
Gross profit | Rs m | 3,247 | 37,070 | 8.8% | |
Depreciation | Rs m | 281 | 12,446 | 2.3% | |
Interest | Rs m | 8 | 1,405 | 0.5% | |
Profit before tax | Rs m | 3,142 | 26,125 | 12.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 6,849 | 12.4% | |
Profit after tax | Rs m | 2,295 | 19,277 | 11.9% | |
Gross profit margin | % | 26.4 | 14.9 | 177.0% | |
Effective tax rate | % | 27.0 | 26.2 | 102.9% | |
Net profit margin | % | 18.7 | 7.8 | 240.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 214,599 | 5.5% | |
Current liabilities | Rs m | 6,791 | 114,938 | 5.9% | |
Net working cap to sales | % | 40.0 | 40.1 | 99.8% | |
Current ratio | x | 1.7 | 1.9 | 92.4% | |
Inventory Days | Days | 263 | 21 | 1,274.4% | |
Debtors Days | Days | 343 | 66 | 523.7% | |
Net fixed assets | Rs m | 10,617 | 176,668 | 6.0% | |
Share capital | Rs m | 166 | 586 | 28.3% | |
"Free" reserves | Rs m | 7,265 | 267,813 | 2.7% | |
Net worth | Rs m | 7,431 | 268,399 | 2.8% | |
Long term debt | Rs m | 0 | 6,190 | 0.0% | |
Total assets | Rs m | 22,330 | 392,125 | 5.7% | |
Interest coverage | x | 409.1 | 19.6 | 2,087.3% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.6 | 86.9% | |
Return on assets | % | 10.3 | 5.3 | 195.5% | |
Return on equity | % | 30.9 | 7.2 | 430.0% | |
Return on capital | % | 42.4 | 10.0 | 422.8% | |
Exports to sales | % | 0 | 33.7 | 0.0% | |
Imports to sales | % | 13.1 | 15.3 | 85.3% | |
Exports (fob) | Rs m | NA | 83,703 | 0.0% | |
Imports (cif) | Rs m | 1,605 | 38,060 | 4.2% | |
Fx inflow | Rs m | 1,465 | 85,483 | 1.7% | |
Fx outflow | Rs m | 1,605 | 41,447 | 3.9% | |
Net fx | Rs m | -140 | 44,036 | -0.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 23,868 | 9.9% | |
From Investments | Rs m | -215 | -39,778 | 0.5% | |
From Financial Activity | Rs m | -985 | 18,144 | -5.4% | |
Net Cashflow | Rs m | 1,160 | 2,298 | 50.5% |
Indian Promoters | % | 0.0 | 48.8 | - | |
Foreign collaborators | % | 51.8 | 3.1 | 1,687.9% | |
Indian inst/Mut Fund | % | 20.0 | 41.3 | 48.4% | |
FIIs | % | 6.2 | 18.0 | 34.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 48.2 | 100.0% | |
Shareholders | 56,778 | 244,575 | 23.2% | ||
Pledged promoter(s) holding | % | 0.0 | 22.2 | - |
Compare PROCTER & GAMBLE HEALTH With: CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | Aurobindo Pharma | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.18% | 1.70% | 0.97% |
1-Month | -0.72% | 4.69% | 2.08% |
1-Year | -0.85% | 83.87% | 55.37% |
3-Year CAGR | -8.62% | 4.31% | 15.04% |
5-Year CAGR | 5.02% | 6.73% | 19.56% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the Aurobindo Pharma share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of Aurobindo Pharma the stake stands at 51.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of Aurobindo Pharma.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
Aurobindo Pharma paid Rs 3.0, and its dividend payout ratio stood at 9.1%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of Aurobindo Pharma.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.